Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income: 2014-2024

Historic Non Operating Income for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to $18.9 million.

  • Voyager Therapeutics' Non Operating Income fell 41.72% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 20.10%. This contributed to the annual value of $18.9 million for FY2024, which is 61.63% up from last year.
  • As of FY2024, Voyager Therapeutics' Non Operating Income stood at $18.9 million, which was up 61.63% from $11.7 million recorded in FY2023.
  • Over the past 5 years, Voyager Therapeutics' Non Operating Income peaked at $18.9 million during FY2024, and registered a low of $2.8 million during FY2021.
  • Moreover, its 3-year median value for Non Operating Income was $11.7 million (2023), whereas its average is $11.7 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first slumped by 69.96% in 2021, then spiked by 163.76% in 2023.
  • Voyager Therapeutics' Non Operating Income (Yearly) stood at $9.4 million in 2020, then plummeted by 69.96% to $2.8 million in 2021, then skyrocketed by 58.13% to $4.4 million in 2022, then soared by 163.76% to $11.7 million in 2023, then skyrocketed by 61.63% to $18.9 million in 2024.